FLT3 and acute myeloid leukemia: The RATIFY trial [118] was a randomized, placebo-controlled phase 3 trial investigating the addition of MIDO to standard induction chemotherapy and high-dose cytarabine (HiDAC) consolidation in adult patients under the age of 60 with ND AML and FLT3 mutations (TKD or ITD).